公开(公告)号：WO2022013412A1

公开(公告)日：2022-01-20

申请号：PCT/EP2021/069920

申请日：2021-07-16

Applicant: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS

Inventor： GUTIÉRREZ RODRÍGUEZ, Marta ,  IZQUIERDO GARCÍA, Carolina ,  GASTAMINZA LANDART, Pablo ,  GARAIGORTA DE DIOS, Urtzi

IPC: C07D215/52 ,  A61P31/14 ,  A61K31/47

Abstract: The present invention relates to new derivatives of 2-phenyl-quinoline-4-carboxylic acid or pharmaceutically acceptable salt thereof and to combination of said compounds with other active ingredients, for use in the treatment and/or prevention of viral infections by virus from the family Coronaviridae, to the use of said compound or its combinations in the manufacture of a medicament for the treatment or prevention of said diseases and to a method of treating and/or preventing said diseases by administration of said compound or its combinations.

公开(公告)号：WO2020185805A1

公开(公告)日：2020-09-17

申请号：PCT/US2020/021939

申请日：2020-03-11

Applicant: CLEAR CREEK BIO, INC.

Inventor： SYKES, David, Brian ,  KUMAR, Vikram, S. ,  LEVIN, Andrew, D. ,  SCADDEN, David ,  ADELMAN, Burt, Alan

IPC: A61K31/47 ,  A61K39/395 ,  A61P35/00 ,  C07D215/52 ,  C07K16/28

Abstract: The invention provides technologies for the improvement of immuno-oncology therapy. The present disclosure encompasses the recognition that brequinar may be useful in improving the safety and efficacy of immuno-oncology (IO) treatments. The goal of IO is to use patient's own immune system to eliminate cancerous cells. Examples of IO treatments may include hematopoietic stem cell transplantation (HSCT), cancer vaccines (alone or in combination with adoptive T cell immunotherapy), monoclonal antibodies (mAbs), and chimeric antigen receptor (CAR) T cell therapy.

公开(公告)号：WO2016146602A1

公开(公告)日：2016-09-22

申请号：PCT/EP2016/055489

申请日：2016-03-15

Applicant: BAYER PHARMA AKTIENGESELLSCHAFT

Inventor： BECK, Hartmut ,  THALER, Tobias ,  KAST, Raimund ,  MEININGHAUS, Mark ,  TERJUNG, Carsten ,  MUENSTER, Uwe ,  OLENIK, Britta

IPC: C07D215/52 ,  C07D405/12 ,  C07D409/04 ,  A61K31/47 ,  A61K31/4725 ,  A61P11/00

CPC classification number: A61K31/47 ,  A61K31/16 ,  A61K31/195 ,  C07D215/52 ,  C07D405/12 ,  C07D409/04

Abstract: Die vorliegende Anmeldung betrifft neue substituierte N-Bicyclo-2-arylchinolin-4-carboxamid-Derivate, Verfahren zu ihrer Herstellung, ihre Verwendung allein oder in Kombinationen zur Behandlung und/oder Prävention von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prävention von Krankheiten, insbesondere zur Behandlung und/oder Prävention von fibrotischen und inflammatorischen Erkrankungen.

Abstract translation: 本申请涉及新的取代的N-二环-2- arylquinoline -4-甲酰胺衍生物，它们的制备方法，它们单独使用或者在用于疾病的治疗和/或预防和它们用于制备药物用于治疗用途的组合和/ 或预防的疾病，尤其是对纤维变性和炎性疾病的治疗和/或预防。

公开(公告)号：WO2009082346A1

公开(公告)日：2009-07-02

申请号：PCT/SE2008/051496

申请日：2008-12-18

Applicant: ASTRAZENECA AB ,  BLOMBERG, David ,  BRICKMANN, Kay ,  HOLMÉN, Anders ,  HOVLAND, Ragnar ,  JOHANNESSON, Petra ,  MÅNSSON, Åsa ,  PLOWRIGHT, Alleyn, Thomas ,  SCHNECKE, Volker ,  SÖRME, Pernilla ,  STÅHLBERG, Pernilla ,  WELLNER, Eric

Inventor： BLOMBERG, David ,  BRICKMANN, Kay ,  HOLMÉN, Anders ,  HOVLAND, Ragnar ,  JOHANNESSON, Petra ,  MÅNSSON, Åsa ,  PLOWRIGHT, Alleyn, Thomas ,  SCHNECKE, Volker ,  SÖRME, Pernilla ,  STÅHLBERG, Pernilla ,  WELLNER, Eric

IPC: C07D401/04 ,  A61K31/4725 ,  A61K31/497 ,  A61P3/04 ,  C07C309/32 ,  C07D215/52 ,  C07D403/04 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04

CPC classification number: C07C311/45 ,  C07C271/20 ,  C07C311/18 ,  C07C311/19 ,  C07C2601/14 ,  C07D213/81 ,  C07D213/82 ,  C07D215/36 ,  C07D215/52 ,  C07D217/02 ,  C07D271/06 ,  C07D277/54 ,  C07D277/64 ,  C07D277/82 ,  C07D309/04 ,  C07D319/18 ,  C07D333/34 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/04 ,  C07D417/04

Abstract: The present invention relates to Acetyl Coenzyme A Carboxylase (ACC) inhibitors according to formula (I), or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , R 4 , R 5 , E, L, Z and n are as defined herein, to processes for preparing such compounds, to pharmaceutical compositions containing them, to the use of such inhibitors and to methods for th eir therapeutic use, particularly in the treatments of obesity and diabetes mellitus.

Abstract translation: 本发明涉及式（I）的乙酰辅酶A羧化酶（ACC）抑制剂或其对映异构体或其药学上可接受的盐，其中R1，R2，R3，R4，R5，E，L，Z和n 本文定义的方法，制备此类化合物的方法，含有它们的药物组合物，使用这种抑制剂以及用于治疗用途的方法，特别是在治疗肥胖症和糖尿病中。

公开(公告)号：WO2007069977A1

公开(公告)日：2007-06-21

申请号：PCT/SE2006/001408

申请日：2006-12-11

Applicant: ASTRAZENECA AB ,  SIMPSON, Thomas ,  KANG, James ,  ALBERT, Jeffrey ,  ALHAMBRA, Cristobal ,  KOETHER, Gerard ,  WOODS, James ,  LI, Yan

Inventor： SIMPSON, Thomas ,  KANG, James ,  ALBERT, Jeffrey ,  ALHAMBRA, Cristobal ,  KOETHER, Gerard ,  WOODS, James ,  LI, Yan

IPC: C07D215/52 ,  A61K31/47 ,  A61P25/18 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P3/04 ,  A61P35/00

CPC classification number: C07D215/38 ,  C07D215/14 ,  C07D215/52

Abstract: Compounds of Formula (1), pharmaceutically-acceptable salts, methods of making them, pharmaceutical compositions containing them and methods for their use. The compounds are neurokinin- 3 (NK-3) receptor antagonists and are used in the treatment of diseases such as depression, anxiety, schizophrenia, cognitive disorders, psychoses, obesity, inflammatory diseases, irritable bowel syndrome, inflammatory bowel disorder, emesis, preeclampsia, chronic obstructive pulmonary disease, disorders associated with excessive gonadotrophins and/or androgens including dysmenorrhea, benign prostatic hyperplasia, prostatic cancer and testicular cancer.

Abstract translation: 式（1）的化合物，药学上可接受的盐，其制备方法，含有它们的药物组合物及其使用方法。 化合物是神经激肽-3（NK-3）受体拮抗剂，用于治疗抑郁症，焦虑症，精神分裂症，认知障碍，精神病，肥胖症，炎性疾病，肠易激综合征，炎性肠病，呕吐，先兆子痫等疾病 慢性阻塞性肺疾病，与过度促性腺激素和/或雄激素相关的疾病，包括痛经，良性前列腺增生，前列腺癌和睾丸癌。

公开(公告)号：WO2006130080A3

公开(公告)日：2007-01-25

申请号：PCT/SE2006000630

申请日：2006-05-30

Applicant: ASTRAZENECA AB ,  SIMPSON R THOMAS ,  KANG JAMES ,  ALBERT S JEFFREY ,  ALHAMBRA CRISTOBAL ,  KOETHER M GERARD ,  WOODS M JAMES ,  LI YAN

Inventor： SIMPSON R THOMAS ,  KANG JAMES ,  ALBERT S JEFFREY ,  ALHAMBRA CRISTOBAL ,  KOETHER M GERARD ,  WOODS M JAMES ,  LI YAN

IPC: C07D215/52 ,  A61K31/47 ,  A61P3/04 ,  A61P25/18 ,  A61P25/24

CPC classification number: C07D215/52

Abstract: Compounds of Formula I wherein R 1 , A, R 2 , n, R 3 , m, R 5 and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Abstract translation: 式I的化合物，其中R 1，A，R 2，n，R 3，m，R 5， 和q如说明书中所述，药学上可接受的盐，制备方法，含药物组合物及其使用方法。

公开(公告)号：WO2006094237A2

公开(公告)日：2006-09-08

申请号：PCT/US2006007746

申请日：2006-03-03

Applicant: SIRTRIS PHARMACEUTICALS INC ,  MILBURN MICHAEL ,  MILNE JILL ,  BEMIS JEAN ,  NUNES JOSEPH J ,  XIE ROGER ,  NORMINGTON KARL D

Inventor： MILBURN MICHAEL ,  MILNE JILL ,  BEMIS JEAN ,  NUNES JOSEPH J ,  XIE ROGER ,  NORMINGTON KARL D

IPC: C07D401/12 ,  C07D215/48 ,  C07D215/52 ,  C07D219/04 ,  C07D219/10 ,  C07D405/12 ,  C07D413/04

CPC classification number: C07D401/14 ,  C07D215/48 ,  C07D215/52 ,  C07D219/04 ,  C07D219/10 ,  C07D401/12 ,  C07D405/04 ,  C07D405/12 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12

Abstract: Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, chemo therapeutic induced neuropathy, neuropathy associated with an ischemic event, polyglutamine diseases, ocular diseases and/or disorders, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract translation: 本文提供了新的沉默调节蛋白的调节化合物及其使用方法。 沉默调节蛋白的调节化合物可用于增加细胞的寿命，以及治疗和/或预防各种各样的疾病和病症，包括例如与老化或紧张相关的疾病或病症，糖尿病，肥胖症，神经变性疾病， 化学治疗性诱导的神经病变，与缺血事件相关的神经病变，多聚谷氨酰胺病，眼部疾病和/或病症，心血管疾病，凝血障碍，炎症，癌症和/或潮红。 还提供了包含与另一种治疗剂组合的沉默调节蛋白的调节化合物的组合物。

公开(公告)号：WO2006013393A3

公开(公告)日：2006-02-09

申请号：PCT/GB2005/050120

申请日：2005-07-28

Applicant: MERCK SHARP & DOHME LIMITED ,  CARLING, William Robert ,  ELLIOTT, Jason, Matthew ,  MEZZOGORI, Elena ,  RUSSELL, Michael, Geoffrey, Neil ,  WILLIAMS, Brian, John

Inventor： CARLING, William Robert ,  ELLIOTT, Jason, Matthew ,  MEZZOGORI, Elena ,  RUSSELL, Michael, Geoffrey, Neil ,  WILLIAMS, Brian, John

IPC: C07D215/52

Abstract: The present invention relates to substituted quinoline-4-carboxylic acid hydrazides defined herein, pharmaceutical compositions comprising them and their use in treating diseases mediated by neurokinin-2 and/or neurokinin-3 (NK-3) receptors.

公开(公告)号：WO99014196A1

公开(公告)日：1999-03-25

申请号：PCT/US1998/019434

申请日：1998-09-17

IPC: C07D215/48 ,  A61K31/47 ,  A61P11/06 ,  C07D215/52 ,  C07D491/147 ,  C07D215/12 ,  C07D215/20 ,  C07D215/38

CPC classification number: C07D215/36 ,  C07D215/38 ,  C07D215/52

Abstract: This invention relates to novel intermediates and processes for preparing pharmaceutically active quinoline compounds, including (-)-(S)-N-( alpha -ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide.

Abstract translation: 本发明涉及制备药用活性喹啉化合物的新型中间体和方法，包括（ - ） - （S）-N-（α-乙基苄基）-3-羟基-2-苯基喹啉-4-甲酰胺。

公开(公告)号：WO98057931A2

公开(公告)日：1998-12-23

申请号：PCT/US1998/012762

申请日：1998-06-18

IPC: C07D491/048 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/4738 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61P31/04 ,  C07D209/12 ,  C07D209/14 ,  C07D215/52 ,  C07D401/04 ,  C07D401/14 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D453/02 ,  C07D471/04 ,  C07D491/04 ,  C07D491/056 ,  C07D

CPC classification number: C07D401/14 ,  C07D209/12 ,  C07D209/14 ,  C07D215/52 ,  C07D401/04 ,  C07D405/04 ,  C07D409/04 ,  C07D471/04 ,  C07D491/04

Abstract: The present invention provides methods and pharmaceutical preparations that inhibit the growth of bacterial microorganisms. Additionally, the present invention provides methods and pharmaceutical preparations that kill bacterial microorganisms.

Abstract translation: 本发明提供抑制细菌微生物生长的方法和药物制剂。 此外，本发明提供杀死细菌微生物的方法和药物制剂。